Journal of the Society for Cardiovascular Angiography & Interventions最新文献

英文中文

Stage E Cardiogenic Shock: Hold 'Em, Fold 'Em, or Double Down?

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-02-01 DOI: 10.1016/j.jscai.2024.102498

Alexander G. Truesdell MD , Aditya Mehta MD , Ilan Vavilin MD

引用次数: 0

Rotational Angiography 3D Data Set to Confirm Harmony Valve Fitness Post Pulmonary Artery Plication

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-02-01 DOI: 10.1016/j.jscai.2024.102518

Osamah Aldoss MD , Thomas Panicucci DNP , Bassel Mohammad Nijres MD , Mohsen Karimi MD

A 28-year-old woman presented with heart failure symptoms secondary to severe pulmonary valve regurgitation in the setting of congenital pulmonary valve stenosis that required balloon valvuloplasty. Computed tomography angiography fit analysis demonstrated a severely dilated main pulmonary artery that did not meet the minimum oversizing criteria for placement of a 25-mm Harmony transcatheter pulmonary valve. A hybrid transcatheter pulmonary valve placement approach took place, and a post main pulmonary artery plication right ventricle rotational angiogram was performed. The patient underwent a successful transcatheter pulmonary valve placement. The 3D rotational angiography data set was analyzed, and fit analysis demonstrated an adequate oversizing of the 25-mm transcatheter pulmonary valve.

引用次数: 0

Evaluating Procedural Performance: A Composite Outcome for Atrial Septal Defect and Patent Ductus Arteriosus Closures

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-02-01 DOI: 10.1016/j.jscai.2024.102459

Oliver M. Barry MD , Babar S. Hasan MBBS , Nadeem Aslam MBBS , Sarosh P. Batlivala MD, MSCI , Matthew A. Crystal MD , Sara M. Trucco MD , Todd Gudausky MD , Ralf J. Holzer MD , Jacqueline Kreutzer MD , George Nicholson MD , Michael L. O’Byrne MD, MSCE , Brian P. Quinn MD , Surendranath R. Veeram Reddy MD , Arash Salavitabar MD , Brian A. Boe MD

Background

Technical success (TS) and procedural safety (PS) have been reported individually for transcatheter atrial septal defect (ASD) and patent ductus arteriosus (PDA) closures. A composite procedural performance (PP) metric as a patient-centered strategy has not been developed or studied.

Methods

A multicenter expert working group created PP metrics for ASD and PDA device closures as a composite of TS and PS. TS criteria were defined and categorized into 3 classes (optimal, satisfactory, and unsatisfactory). PS was defined using established adverse event (AE) definitions from the Congenital Cardiac Catheterization Project on Outcomes (C3PO) registry. PP was divided into 3 outcome classes (I to III). Retrospective C3PO data were collected for all cases of isolated ASD and PDA closure from 2014 through 2017. Exclusion criteria included complex congenital heart disease, significant comorbidities, ASD patients with multiple defects or ≥2 deficient rims, and PDA patients weighing <6 kg or with pulmonary hypertension. Factors correlating with class III (suboptimal) PP were analyzed.

Results

A total of 542 ASD and 688 PDA closure cases were included. Most ASD cases (99%) had optimal or satisfactory TS while 1% had a high severity AE. Class III PP occurred in 2% of ASD cases, mostly due to new mitral valve insufficiency. There were no identified patient or procedural factors associated with class III PP for ASD closures. Optimal or satisfactory TS occurred in 98% of PDA cases, with high severity AEs in <1%. Class III PP occurred in 2% of PDA cases, predominantly due to new arch obstruction, and was associated with younger age (P < .001) and lower weight (P = .001).

Conclusions

This study introduces PP as a composite variable to comprehensively measure outcomes of standard-risk ASD and PDA device closure. The incorporation of both TS and PS aims to better reflect patient outcomes compared to individual measurements alone. PP may serve as a valuable tool for identifying areas for further investigation and quality improvement.

{"title":"Evaluating Procedural Performance: A Composite Outcome for Atrial Septal Defect and Patent Ductus Arteriosus Closures","authors":"Oliver M. Barry MD , Babar S. Hasan MBBS , Nadeem Aslam MBBS , Sarosh P. Batlivala MD, MSCI , Matthew A. Crystal MD , Sara M. Trucco MD , Todd Gudausky MD , Ralf J. Holzer MD , Jacqueline Kreutzer MD , George Nicholson MD , Michael L. O’Byrne MD, MSCE , Brian P. Quinn MD , Surendranath R. Veeram Reddy MD , Arash Salavitabar MD , Brian A. Boe MD","doi":"10.1016/j.jscai.2024.102459","DOIUrl":"10.1016/j.jscai.2024.102459","url":null,"abstract":"<div><h3>Background</h3><div>Technical success (TS) and procedural safety (PS) have been reported individually for transcatheter atrial septal defect (ASD) and patent ductus arteriosus (PDA) closures. A composite procedural performance (PP) metric as a patient-centered strategy has not been developed or studied.</div></div><div><h3>Methods</h3><div>A multicenter expert working group created PP metrics for ASD and PDA device closures as a composite of TS and PS. TS criteria were defined and categorized into 3 classes (optimal, satisfactory, and unsatisfactory). PS was defined using established adverse event (AE) definitions from the Congenital Cardiac Catheterization Project on Outcomes (C3PO) registry. PP was divided into 3 outcome classes (I to III). Retrospective C3PO data were collected for all cases of isolated ASD and PDA closure from 2014 through 2017. Exclusion criteria included complex congenital heart disease, significant comorbidities, ASD patients with multiple defects or ≥2 deficient rims, and PDA patients weighing <6 kg or with pulmonary hypertension. Factors correlating with class III (suboptimal) PP were analyzed.</div></div><div><h3>Results</h3><div>A total of 542 ASD and 688 PDA closure cases were included. Most ASD cases (99%) had optimal or satisfactory TS while 1% had a high severity AE. Class III PP occurred in 2% of ASD cases, mostly due to new mitral valve insufficiency. There were no identified patient or procedural factors associated with class III PP for ASD closures. Optimal or satisfactory TS occurred in 98% of PDA cases, with high severity AEs in <1%. Class III PP occurred in 2% of PDA cases, predominantly due to new arch obstruction, and was associated with younger age (<em>P</em> < .001) and lower weight (<em>P</em> = .001).</div></div><div><h3>Conclusions</h3><div>This study introduces PP as a composite variable to comprehensively measure outcomes of standard-risk ASD and PDA device closure. The incorporation of both TS and PS aims to better reflect patient outcomes compared to individual measurements alone. PP may serve as a valuable tool for identifying areas for further investigation and quality improvement.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 2","pages":"Article 102459"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual Antiplatelet Therapy Duration Following Percutaneous Coronary Intervention: Time for a Change

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-02-01 DOI: 10.1016/j.jscai.2024.102510

Dean J. Kereiakes MD

引用次数: 0

The Utility and Validation of SCAI-CSWG Stages in Patients With Acute Myocardial Infarction-Related Cardiogenic Shock

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-01-01 DOI: 10.1016/j.jscai.2024.102461

Rajesh Rajan MD , Mohammed Al Jarallah MD , Amin Daoulah MD , Prashanth Panduranga MD , Ahmed Elmahrouk MD , Abeer Said Mohamed Al Rawahi MD , Said Al Maashani MD , Hatem M. Aloui MD , Mubarak Abdulhadi Aldossari MD , Nooraldaem Yousif MD , Husam A. Noor MD , Abdulrahman Arabi MD , Gi Eun Kim MD , Mohamad Safieh MD , Wael Almahmeed MD , Hassan Khan MD , Mohammed A. Qutub MD , Mohammed Alshehri MD , Amr A. Arafat MD , Omar Kanbr MD , Abdullah N. AlAwadi MD

Background

Outcomes of patients with acute myocardial infarction–related cardiogenic shock (AMICS) stratified by the Society for Cardiovascular Angiography & Interventions (SCAI) shock stages in the Gulf region are not well known.

Methods

We analyzed data from patients with AMICS presenting to multiple centers across the Gulf region between January 2020 and December 2022. Patients were grouped according to SCAI-Cardiogenic Shock Working Group classification: group 1 (SCAI shock stages B/C) and group 2 (SCAI shock stages D/E). Primary end points were survival at 6, 12, 18, and 24 months. Both univariate and multivariate statistical methods were employed in the analysis.

Results

A total of 1513 patients from the Gulf Cardiogenic Shock registry, were included with 31.1% in group 1 and 68.9% in group 2. The median follow-up was 6 months. Survival rates in group 1 were 87%, 72%, 56%, and 48% at 6, 12, 18, and 24 months, respectively, whereas group 2 exhibited survival rates of 66%, 29%, 14%, and 4%, respectively, over the same periods. Survival progressively declined with advancing SCAI shock stages, with stage B having the highest survival rates and stage E the lowest (P < .001). Multivariable Cox regression analysis identified higher SCAI stages as strong predictors of increased mortality, with patients in group 2 having a more than 3-fold higher risk of mortality compared to those in group 1 (hazard ratio, 3.13; 95% CI, 2.40-4.07; P < .001). Additionally, lower left ventricular ejection fraction, advanced age, and the presence of tachyarrhythmias were associated with increased mortality risk.

Conclusions

This is the first study to validate SCAI-Cardiogenic Shock Working Group stages in a large cohort of patients with AMICS. The SCAI shock staging classification was significantly associated with higher short- and long-term mortality in this cohort, with patients in more advanced stages (D/E) experiencing markedly worse survival outcomes. These findings underscore the utility of SCAI staging in stratifying long-term risk among AMICS patients in the Gulf region. Identification of cardiogenic shock patients at SCAI stages D and E with early hemodynamic monitoring and treating them aggressively with newer mechanical circulatory support in the early stages may improve patient survival.

{"title":"The Utility and Validation of SCAI-CSWG Stages in Patients With Acute Myocardial Infarction-Related Cardiogenic Shock","authors":"Rajesh Rajan MD , Mohammed Al Jarallah MD , Amin Daoulah MD , Prashanth Panduranga MD , Ahmed Elmahrouk MD , Abeer Said Mohamed Al Rawahi MD , Said Al Maashani MD , Hatem M. Aloui MD , Mubarak Abdulhadi Aldossari MD , Nooraldaem Yousif MD , Husam A. Noor MD , Abdulrahman Arabi MD , Gi Eun Kim MD , Mohamad Safieh MD , Wael Almahmeed MD , Hassan Khan MD , Mohammed A. Qutub MD , Mohammed Alshehri MD , Amr A. Arafat MD , Omar Kanbr MD , Abdullah N. AlAwadi MD","doi":"10.1016/j.jscai.2024.102461","DOIUrl":"10.1016/j.jscai.2024.102461","url":null,"abstract":"<div><h3>Background</h3><div>Outcomes of patients with acute myocardial infarction–related cardiogenic shock (AMICS) stratified by the Society for Cardiovascular Angiography & Interventions (SCAI) shock stages in the Gulf region are not well known.</div></div><div><h3>Methods</h3><div>We analyzed data from patients with AMICS presenting to multiple centers across the Gulf region between January 2020 and December 2022. Patients were grouped according to SCAI-Cardiogenic Shock Working Group classification: group 1 (SCAI shock stages B/C) and group 2 (SCAI shock stages D/E). Primary end points were survival at 6, 12, 18, and 24 months. Both univariate and multivariate statistical methods were employed in the analysis.</div></div><div><h3>Results</h3><div>A total of 1513 patients from the Gulf Cardiogenic Shock registry, were included with 31.1% in group 1 and 68.9% in group 2. The median follow-up was 6 months. Survival rates in group 1 were 87%, 72%, 56%, and 48% at 6, 12, 18, and 24 months, respectively, whereas group 2 exhibited survival rates of 66%, 29%, 14%, and 4%, respectively, over the same periods. Survival progressively declined with advancing SCAI shock stages, with stage B having the highest survival rates and stage E the lowest (<em>P</em> < .001). Multivariable Cox regression analysis identified higher SCAI stages as strong predictors of increased mortality, with patients in group 2 having a more than 3-fold higher risk of mortality compared to those in group 1 (hazard ratio, 3.13; 95% CI, 2.40-4.07; <em>P</em> < .001). Additionally, lower left ventricular ejection fraction, advanced age, and the presence of tachyarrhythmias were associated with increased mortality risk.</div></div><div><h3>Conclusions</h3><div>This is the first study to validate SCAI-Cardiogenic Shock Working Group stages in a large cohort of patients with AMICS. The SCAI shock staging classification was significantly associated with higher short- and long-term mortality in this cohort, with patients in more advanced stages (D/E) experiencing markedly worse survival outcomes. These findings underscore the utility of SCAI staging in stratifying long-term risk among AMICS patients in the Gulf region. Identification of cardiogenic shock patients at SCAI stages D and E with early hemodynamic monitoring and treating them aggressively with newer mechanical circulatory support in the early stages may improve patient survival.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 1","pages":"Article 102461"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143168527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-01-01 DOI: 10.1016/j.jscai.2024.102463

Mona Ranade MD , Malcolm T. Foster III MD , Paul S. Brady MD , Seth I. Sokol MD , Sabah Butty MD , Andrew Klein MD , Robert Maholic DO , Ammar Safar MD , Taral Patel MD , David Zlotnick MD , Daniel Gans MD , Jeffrey Pollak MD , Dean Ferrera DO , Brian Stegman MD , Sukhdeep Basra MD , John Moriarty MD , Brent Keeling MD , APEX-AV Investigators

Background

There is a need for additional data to assess procedural efficacy and risks associated with mechanical thrombectomy for treating pulmonary embolism (PE) due to its increased utilization and diversity of patient populations presenting with PE. This study evaluated the safety and efficacy of percutaneous mechanical aspiration thrombectomy with the AlphaVac F18⁸⁵ System (AngioDynamics) in patients with acute intermediate-risk PE.

Methods

Patients with acute intermediate-risk PE and a right ventricular (RV)/left ventricular (LV) diameter ratio of ≥0.9 were eligible for enrollment in this prospective, multicenter, single-arm study. The primary effectiveness end point was reduction in the RV/LV ratio at 48 hours. The primary safety end point was the rate of major adverse events (MAEs) defined as subjects who experienced major bleeding, device-related deaths, clinical deterioration, or pulmonary vascular or cardiac injury within 48 hours postprocedurally.

Results

In total, 122 subjects were enrolled at 25 sites. Mean procedure time was 37.2 ± 17.7 minutes. There were statistically significant reductions in mean 48-hour postprocedural RV/LV diameter ratio (−0.45 ± 0.27; P < .001). Postprocedural mean pulmonary arterial pressure also significantly declined from 27.8 ± 7.8 mm Hg before the procedure to 21.8 ± 7.2 mm Hg (P < .001). There was a 35.5% mean reduction in clot burden as measured by the modified Miller index score. Five (4.1%) subjects developed 7 MAEs during the postprocedural 48-hour assessment period, the majority of which were access site bleeding.

Conclusions

Percutaneous mechanical aspiration thrombectomy with the AlphaVac system provided a safe and effective treatment for acute intermediate-risk PE with a significant reduction in RV/LV ratio and clot burden with a low rate of adverse events.

{"title":"Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial","authors":"Mona Ranade MD , Malcolm T. Foster III MD , Paul S. Brady MD , Seth I. Sokol MD , Sabah Butty MD , Andrew Klein MD , Robert Maholic DO , Ammar Safar MD , Taral Patel MD , David Zlotnick MD , Daniel Gans MD , Jeffrey Pollak MD , Dean Ferrera DO , Brian Stegman MD , Sukhdeep Basra MD , John Moriarty MD , Brent Keeling MD , APEX-AV Investigators","doi":"10.1016/j.jscai.2024.102463","DOIUrl":"10.1016/j.jscai.2024.102463","url":null,"abstract":"<div><h3>Background</h3><div>There is a need for additional data to assess procedural efficacy and risks associated with mechanical thrombectomy for treating pulmonary embolism (PE) due to its increased utilization and diversity of patient populations presenting with PE. This study evaluated the safety and efficacy of percutaneous mechanical aspiration thrombectomy with the AlphaVac F18<sup>85</sup> System (AngioDynamics) in patients with acute intermediate-risk PE.</div></div><div><h3>Methods</h3><div>Patients with acute intermediate-risk PE and a right ventricular (RV)/left ventricular (LV) diameter ratio of ≥0.9 were eligible for enrollment in this prospective, multicenter, single-arm study. The primary effectiveness end point was reduction in the RV/LV ratio at 48 hours. The primary safety end point was the rate of major adverse events (MAEs) defined as subjects who experienced major bleeding, device-related deaths, clinical deterioration, or pulmonary vascular or cardiac injury within 48 hours postprocedurally.</div></div><div><h3>Results</h3><div>In total, 122 subjects were enrolled at 25 sites. Mean procedure time was 37.2 ± 17.7 minutes. There were statistically significant reductions in mean 48-hour postprocedural RV/LV diameter ratio (−0.45 ± 0.27; <em>P</em> < .001). Postprocedural mean pulmonary arterial pressure also significantly declined from 27.8 ± 7.8 mm Hg before the procedure to 21.8 ± 7.2 mm Hg (<em>P</em> < .001). There was a 35.5% mean reduction in clot burden as measured by the modified Miller index score. Five (4.1%) subjects developed 7 MAEs during the postprocedural 48-hour assessment period, the majority of which were access site bleeding.</div></div><div><h3>Conclusions</h3><div>Percutaneous mechanical aspiration thrombectomy with the AlphaVac system provided a safe and effective treatment for acute intermediate-risk PE with a significant reduction in RV/LV ratio and clot burden with a low rate of adverse events.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 1","pages":"Article 102463"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143168862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addition by Subtraction: A Novel Device for Pulmonary Embolus Thrombectomy

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-01-01 DOI: 10.1016/j.jscai.2024.102508

Joseph M. Kim MD , Eric A. Secemsky MD, MSc

引用次数: 0

Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-01-01 DOI: 10.1016/j.jscai.2024.102432

Andrew W. Schwartz BS , Yousuf Shah MD , Haocheng Huang MS , Ashwin Nathan MD, MSHP , Alexander C. Fanaroff MD, MHS , Jay S. Giri MD, MPH , Sahil A. Parikh MD , Alexandra J. Lansky MD , Tayyab Shah MD

Background

To understand the relative safety and efficacy of endovascular treatment modalities used for superficial femoral artery (SFA) disease, we performed a network meta-analysis to compare outcomes between percutaneous transluminal angioplasty (PTA), atherectomy (A), bare metal stent (BMS), brachytherapy/radiotherapy, covered stent graft (CSG), cutting balloon angioplasty (CBA), drug-coated balloon (DCB), drug-eluting stent (DES), and intravascular lithotripsy (L).

Methods

We performed a systematic literature search of PubMed from January 2000 to January 2023 to identify randomized trials comparing endovascular interventions for the treatment of SFA disease. The primary end points were technical success and 12-month primary patency.

Results

In total, 57 studies (9089 patients) were included. The mean age of the included patients was 68.4 years, 41.4% had diabetes, 18.3% had critical limb ischemia, and 81.3% had de novo lesions. A mean of 1.2 lesions were treated per patient. Technical success was superior for CSG, BMS, and A+DCB compared with PTA, while A+DCB and CSG were superior to DCB. All interventions except brachytherapy alone had superior primary patency compared with PTA. There were no significant differences in 12-month mortality or major amputation. All interventions except L+DCB, PTA+A, and CBA were superior to PTA regarding target lesion revascularization, while only DCB, DES, and BMS were better than PTA at improving Rutherford classification.

Conclusions

In SFA disease, PTA alone is mostly inferior to other endovascular techniques. This comparison of other endovascular techniques will be valuable for endovascular device selection in the treatment of SFA disease.

{"title":"Comparison of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis","authors":"Andrew W. Schwartz BS , Yousuf Shah MD , Haocheng Huang MS , Ashwin Nathan MD, MSHP , Alexander C. Fanaroff MD, MHS , Jay S. Giri MD, MPH , Sahil A. Parikh MD , Alexandra J. Lansky MD , Tayyab Shah MD","doi":"10.1016/j.jscai.2024.102432","DOIUrl":"10.1016/j.jscai.2024.102432","url":null,"abstract":"<div><h3>Background</h3><div>To understand the relative safety and efficacy of endovascular treatment modalities used for superficial femoral artery (SFA) disease, we performed a network meta-analysis to compare outcomes between percutaneous transluminal angioplasty (PTA), atherectomy (A), bare metal stent (BMS), brachytherapy/radiotherapy, covered stent graft (CSG), cutting balloon angioplasty (CBA), drug-coated balloon (DCB), drug-eluting stent (DES), and intravascular lithotripsy (L).</div></div><div><h3>Methods</h3><div>We performed a systematic literature search of PubMed from January 2000 to January 2023 to identify randomized trials comparing endovascular interventions for the treatment of SFA disease. The primary end points were technical success and 12-month primary patency.</div></div><div><h3>Results</h3><div>In total, 57 studies (9089 patients) were included. The mean age of the included patients was 68.4 years, 41.4% had diabetes, 18.3% had critical limb ischemia, and 81.3% had de novo lesions. A mean of 1.2 lesions were treated per patient. Technical success was superior for CSG, BMS, and A+DCB compared with PTA, while A+DCB and CSG were superior to DCB. All interventions except brachytherapy alone had superior primary patency compared with PTA. There were no significant differences in 12-month mortality or major amputation. All interventions except L+DCB, PTA+A, and CBA were superior to PTA regarding target lesion revascularization, while only DCB, DES, and BMS were better than PTA at improving Rutherford classification.</div></div><div><h3>Conclusions</h3><div>In SFA disease, PTA alone is mostly inferior to other endovascular techniques. This comparison of other endovascular techniques will be valuable for endovascular device selection in the treatment of SFA disease.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 1","pages":"Article 102432"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143168864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in Radiation Use in Left Atrial Appendage Occlusion Procedures Among Electrophysiology and Structural Operators

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-01-01 DOI: 10.1016/j.jscai.2024.102458

Zachary Dean Demertzis DO , Ela Ahmad MD , Karan Chhabra MBBS , Nolan Shoukri BS , David Haines MD , Simon Dixon MBChB , Nishaki Mehta MD

引用次数: 0

Pulmonary Hypertension and Acute Heart Failure Following Lumbar Disc Surgery

Journal of the Society for Cardiovascular Angiography & Interventions

Pub Date : 2025-01-01 DOI: 10.1016/j.jscai.2024.102453

Bárbara Lacerda Teixeira MD, André Grazina MD, Luís Almeida Morais MD, Ana Galrinho MD, Rui Cruz Ferreira MD

A 70-year-old woman was admitted with heart failure and signs of pulmonary hypertension on echocardiogram. Cardiac catheterization demonstrated postcapillary pulmonary hypertension, elevated cardiac output, and O₂ saturation enrichment. Computed tomography revealed a large arteriovenous fistula between the common iliac artery and vein, which was due to a lumbar disc surgery performed several years prior.

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of the Society for Cardiovascular Angiography & Interventions

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀